Results 131 to 140 of about 19,943,678 (222)

Osteoarthritis Therapeutics: From Microenvironment Understanding to Regenerative Intervention—Current Advances and Future Perspectives

Orthopaedic Surgery, Volume 18, Issue 10, Page 2032-2044, October 2026.
This article outlines a paradigm shift in OA therapeutics, OA as a systemic disease of joint microenvironment imbalance. It synthesizes advances in targeting key pathological hubs—immune, metabolic, and senescent—and details novel regenerative strategies using engineered biomaterials and exosomes.
Yongbiao Meng, Shenghua Wu, Quanchun Liu
wiley   +1 more source

Acute coronary syndrome in patients treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants: Proposed management algorithm for the first 48 hours

International audienceAround 10% of patients with acute coronary syndrome are treated by vitamin K antagonists or non-vitamin K antagonist oral anticoagulants for various indications.
Daller, Marlène, Rochette, Luc, Salaun, Alexandre, de Maistre, Emmanuel, Sombrun, Chan, Fauchier, Laurent, Chagué, Frédéric, Zeller, Marianne, Danchin, Nicolas, Cottin, Yves, Bichat, Florence   +10 more
core   +1 more source

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal

Therapeutics and Clinical Risk Management, 2018
Marco Proietti,1–3 Giuseppe Boriani4 1Department of Neuroscience, IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy; 2Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK ...
Proietti M, Boriani G
doaj  

Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation‐Related Stroke

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background This study aimed to describe the temporal evolution of antithrombotic treatment strategies and associated clinical outcomes after atrial fibrillation‐related acute ischemic stroke.
Keon‐Joo Lee, Hoonji Oh, Han‐Gil Jeong, Beom Joon Kim, Moon‐Ku Han, Joon‐Tae Kim, Kang‐Ho Choi, Dong‐Ick Shin, Jae‐Kwan Cha, Dae‐Hyun Kim, Dong‐Eog Kim, Jong‐Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Mi‐Sun Oh, Kyung‐Ho Yu, Byung‐Chul Lee, Keun‐Sik Hong, Yong‐Jin Cho, Jay Chol Choi, Tai Hwan Park, Kyungbok Lee, Jee‐Hyun Kwon, Wook‐Joo Kim, Jun Lee, Ji Sung Lee, Da Young Hong, Juneyoung Lee, Philip B. Gorelick, Hee‐Joon Bae   +30 more
doaj   +1 more source

Non-Vitamin K Antagonist Versus Vitamin K Antagonist Oral Anticoagulant Agents After Transcatheter Aortic Valve Replacement. [PDF]

BACKGROUND Studies comparing long-term outcomes between non-vitamin K antagonist (VKA) oral anticoagulant agents (direct oral anticoagulant agents [DOACs]) and VKA anticoagulant agents after transcatheter aortic valve replacement (TAVR) are scarce ...
Tueller, D., Roffi, Marco, Stortecky, S., Pilgrim, T., Noble, S., Templin, C., Heg, D., Huber, Christoph, Roffi, M., Templin, Christian, Reuthebuch, O., Noble, Stéphane Laurent, Alaour, B., Muller, O., Jeger, R., Windecker, S., Toggweiler, Stefan, Wenaweser, P., Heg, Dik, Muller, Olivier, Windecker, Stephan, Noble, Stephane, Alaour, Bashir, Ferrari, Enrico, Nietlispach, F., Wenaweser, Peter, Nietlispach, Fabian, Stortecky, Stefan, Toggweiler, S., Ferrari, E., Jeger, Raban, Pilgrim, Thomas, Tueller, David, Reuthebuch, Oliver, Taramasso, M., Huber, C., Taramasso, Maurizio   +36 more
core   +1 more source

Self-reported treatment burden: A comparison between vitamin K and non-vitamin K oral anticoagulants

Exploratory Research in Clinical and Social Pharmacy
Introduction: Treatment burden (TBN) refers to the impact of patients' healthcare-related workload on their functioning and well-being. A high TBN has been associated with lower adherence to treatment and increased risk of major adverse events, and ...
Miroslav Mihajlovic, Nevena Zec, Jelena Simic, Aleksandar Mihajlovic, Milan Marinkovic, Nebojsa Mujovic, Tatjana Potpara   +6 more
doaj   +1 more source

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in Japanese Patients With Atrial Fibrillation

, 2014
Atrial fibrillation; Japanese; Meta-analysis; Non-vitamin K antagonist oral anticoagulant; Stroke preventionBackground: Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as alternatives to warfarin.
Senoo, K, Lip, G.Y.H., Lau, Y. C, Lane, D., Yee Cheng Lau, Okumura, K, Lip, G.Y.H, Senoo, K., Okumura, K., Dzeshka, M.   +9 more
core   +2 more sources

Ex Vivo Antiplatelet Effects of Oral Anticoagulants

Journal of Cardiovascular Development and Disease
Background: The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on platelet function is still unclear. We conducted a comprehensive ex vivo study aimed at assessing the effect of the four currently marketed NOACs on platelet function ...
Giulia Renda, Valentina Bucciarelli, Giulia Barbieri, Paola Lanuti, Martina Berteotti, Gelsomina Malatesta, Francesca Cesari, Tanya Salvatore, Betti Giusti, Anna Maria Gori, Rossella Marcucci, Raffaele De Caterina   +11 more
doaj   +1 more source

Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer

, 2017
Introduction The safety and efficacy of direct oral anticoagulants in cancer patients is currently unclear. Low-molecular-weight heparin remains the standard of care for cancer patients with venous thromboembolism, with warfarin, a vitamin K antagonist ...
Eleanor C Hobaugh, David Putney, Jose R Murillo, Elizabeth R Pritchard   +3 more
core   +1 more source

Guest Editorial A Brave New World for Non-vitamin K Antagonist Oral Anticoagulants: Have We seen the Last of Warfarin?

, 2017
The use of non-vitamin K antagonist oral anticoagulants (NVKA) for antithrombotic treatment has freed patients with atrial fibrillation (AF) from the inconvenience and expense of international normalized ratio measurements.
Michela Faggioni, null null, Roxana Mehran, Michael C Gibson   +3 more
core   +1 more source